Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjögren’s syndrome: underlying immunological mechanisms, clinical presentation, and management. Front Immunol. 2019;10:1327. https://doi.org/10.3389/fimmu.2019.01327.
Odani T, Chiorini JA. Targeting primary Sjögren’s syndrome. Mod Rheumatol. 2019;29(1):70–86. https://doi.org/10.1080/14397595.2018.1546268.
Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–44. https://doi.org/10.1001/archinte.165.20.2337.
Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378(10):931–9. https://doi.org/10.1056/NEJMcp1702514.
Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjögren’s syndrome. Arch Med Res. 2006;37(8):921–32. https://doi.org/10.1016/j.arcmed.2006.08.002.
Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjögren’s syndrome. Rheum Dis Clin North Am. 2008;34(4):833–45. https://doi.org/10.1016/j.rdc.2008.08.004.
Moutsopoulos HM. Sjögren’s syndrome: a forty-year scientific journey. J Autoimmun. 2014;51:1–9. https://doi.org/10.1016/j.jaut.2014.01.001.
Parisis D, Chivasso C, Perret J, Soyfoo MS, Delporte C. Current state of knowledge on primary Sjögren’s syndrome, an autoimmune exocrinopathy. J Clin Med. 2020;9(7):2299. https://doi.org/10.3390/jcm9072299.
Villalon L, Mamani M, Romanini FE, Catalan PA, Berra A. Primary Sjögren’s syndrome: expression of NF-kappaB in minor salivary glands. Reumatol Clin. 2010;6(6):292–5. https://doi.org/10.1016/j.reuma.2009.10.009.
Wakamatsu TH, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim OM, et al. Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Invest Ophthalmol Vis Sci. 2013;54(1):201–10. https://doi.org/10.1167/iovs.12-10325.
Byun YS, Lee HJ, Shin S, Chung SH. Elevation of autophagy markers in Sjögren syndrome dry eye. Sci Rep. 2017;7(1):17280. https://doi.org/10.1038/s41598-017-17128-0.
Li B, Wang F, Schall N, Muller S. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018;90:132–45. https://doi.org/10.1016/j.jaut.2018.02.005.
Nakamura H, Horai Y, Shimizu T, Kawakami A. Modulation of apoptosis by cytotoxic mediators and cell-survival molecules in Sjögren’s syndrome. Int J Mol Sci. 2018;19(8):2369. https://doi.org/10.3390/ijms19082369.
Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. Arthritis Rheum. 2005;52(5):1517–21. https://doi.org/10.1002/art.21005.
Cortes-Troncoso J, Jang SI, Perez P, Hidalgo J, Ikeuchi T, Greenwell-Wild T, et al. T cell exosome-derived miR-142-3p impairs glandular cell function in Sjögren’s syndrome. JCI. JCI Insight. 2020;5(9):e133497. https://doi.org/10.1172/jci.insight.133497.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of Sjögren’s syndrome. Dtsch Arztebl Int. 2017;114(20):354–61. https://doi.org/10.3238/arztebl.2017.0354.
Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sjögren’s syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191–200. https://doi.org/10.7150/ijms.17718.
Puéchal X. Granulomatosis with polyangiitis (Wegener’s). Joint Bone Spine. 2020;87(6):572–8. https://doi.org/10.1016/j.jbspin.2020.06.005.
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puechal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. https://doi.org/10.7326/M13-1085.
Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–31. https://doi.org/10.1136/annrheumdis-2013-203991.
Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–6. https://doi.org/10.1136/annrheumdis-2013-204653.
Fiore A, Murray PJ. Tryptophan and indole metabolism in immune regulation. Curr Opin Immunol. 2021;70:7–14. https://doi.org/10.1016/j.coi.2020.12.001.
Claustrat B, Leston J. Melatonin: physiological effects in humans. Neurochirurgie. 2015;61(2-3):77–84. https://doi.org/10.1016/j.neuchi.2015.03.002.
Reiter RJ, Rosales-Corral SA, Liu XY, Acuna-Castroviejo D, Escames G, Tan DX. Melatonin in the oral cavity: physiological and pathological implications. J Periodontal Res. 2015;50(1):9–17. https://doi.org/10.1111/jre.12176.
Carrascal L, Nunez-Abades P, Ayala A, Cano M. Role of melatonin in the inflammatory process and its therapeutic potential. Curr Pharm Des. 2018;24(14):1563–88. https://doi.org/10.2174/1381612824666180426112832.
Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29(5):325–33. https://doi.org/10.1152/physiol.00011.2014.
Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 2010;80(12):1844–52. https://doi.org/10.1016/j.bcp.2010.07.041.
Cipolla-Neto J, Amaral F. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990–1028. https://doi.org/10.1210/er.2018-00084.
Zhao CN, Wang P, Mao YM, Dan YL, Wu Q, Li XM, et al. Potential role of melatonin in autoimmune diseases. Cytokine Growth Factor Rev. 2019;48:1–10. https://doi.org/10.1016/j.cytogfr.2019.07.002.
Miller E, Walczak A, Majsterek I, Kedziora J. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol. 2013;257(1-2):97–101. https://doi.org/10.1016/j.jneuroim.2013.02.012.
Lopez-Gonzalez A, Alvarez-Sanchez N, Lardone PJ, Cruz-Chamorro I, Martinez-Lopez A, Guerrero JM, et al. Melatonin treatment improves primary progressive multiple sclerosis: a case report. J Pineal Res. 2015;58(2):173–7. https://doi.org/10.1111/jpi.12203.
Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC. Blood pressure-lowering effect of melatonin in type 1 diabetes. J Pineal Res. 2004;36(4):262–6. https://doi.org/10.1111/j.1600-079X.2004.00126.x.
Rasheed AB, Daoud MS, Gorial FI. Diagnostic utility of serum melatonin levels in systemic lupus erythematosus: a case-control study. Reumatismo. 2017;69(4):170–4. https://doi.org/10.4081/reumatismo.2017.998.
Robeva R, Tanev D, Kirilov G, Stoycheva M, Tomova A, Kumanov P, et al. Decreased daily melatonin levels in women with systemic lupus erythematosus - a short report. Balkan Med J. 2013;30(3):273–6. https://doi.org/10.5152/balkanmedj.2013.8064.
Medrano-Campillo P, Sarmiento-Soto H, Alvarez-Sanchez N, Alvarez-Rios AI, Guerrero JM, Rodriguez-Prieto I, et al. Evaluation of the immunomodulatory effect of melatonin on the T-cell response in peripheral blood from systemic lupus erythematosus patients. J Pineal Res. 2015;58(2):219–26. https://doi.org/10.1111/jpi.12208.
Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, Klupinska G, Jaworek J, Chojnacki J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol. 2011;62(3):327–34.
Keskin G, Keskin D, Inal A, Ilikci R. Serum melatonin levels in Sjögren patients (HUM7P. 310). J Immunol. 2014;192(1_Supplement):184.19.
Liu Y, Chen XQ, Wang F, Cheng B, Zhou G. Melatonin relieves Th17/CD4(-)CD8(-) T cells inflammatory responses via nuclear-receptor dependent manner in peripheral blood of primary Sjögren’s syndrome. Int Immunopharmacol. 2022;109:108778. https://doi.org/10.1016/j.intimp.2022.108778.
Liu Y, Weng X, Wei M, Yu S, Ding Y, Cheng B. Melatonin regulates the immune response and improves Sjögren’s syndrome-like symptoms in NOD/Ltj Mice. Biochem Pharmacol. 2022;201:115073. https://doi.org/10.1016/j.bcp.2022.115073.
Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren’s syndrome. Nat Rev Rheumatol. 2010;6(9):529–37. https://doi.org/10.1038/nrrheum.2010.118.
Verstappen GM, Kroese F, Bootsma H. T cells in primary Sjögren’s syndrome: targets for early intervention. Rheumatology (Oxford). 2019;60(7):3088–98. https://doi.org/10.1093/rheumatology/kez004.
Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren’s syndrome. Br J Rheumatol. 1995;34(4):326–33. https://doi.org/10.1093/rheumatology/34.4.326.
Verstappen GM, Corneth O, Bootsma H, Kroese F. Th17 cells in primary Sjögren’s syndrome: pathogenicity and plasticity. J Autoimmun. 2018;87:16–25. https://doi.org/10.1016/j.jaut.2017.11.003.
留言 (0)